243 related articles for article (PubMed ID: 24574825)
1. Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris.
Aldakkak M; Stowe DF; Camara AK
Clin Med Insights Ther; 2013 Jan; 2013(5):1-14. PubMed ID: 24574825
[TBL] [Abstract][Full Text] [Related]
2. New Anti-Anginal Drugs: Ranolazine.
Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
[TBL] [Abstract][Full Text] [Related]
3. Ranolazine (Ranexa) for chronic stable angina.
Ndegwa S
Issues Emerg Health Technol; 2007 Jun; (99):1-6. PubMed ID: 17595750
[TBL] [Abstract][Full Text] [Related]
4. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
[TBL] [Abstract][Full Text] [Related]
5. Emerging clinical role of ranolazine in the management of angina.
Vadnais DS; Wenger NK
Ther Clin Risk Manag; 2010 Oct; 6():517-30. PubMed ID: 21063462
[TBL] [Abstract][Full Text] [Related]
6. Ranolazine: effects on ischemic heart.
Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
[TBL] [Abstract][Full Text] [Related]
7. Ranolazine in patients with coronary artery disease.
Scirica BM
Expert Opin Pharmacother; 2007 Sep; 8(13):2149-57. PubMed ID: 17714067
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
Rosano GMC; Vitale C; Volterrani M
Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
[TBL] [Abstract][Full Text] [Related]
9. Ranolazine: a new option in the management of chronic stable angina.
Dobesh PP; Trujillo TC
Pharmacotherapy; 2007 Dec; 27(12):1659-76. PubMed ID: 18041887
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine: a new approach to treating an old problem.
Reddy BM; Weintraub HS; Schwartzbard AZ
Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
Bhandari B; Subramanian L
Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
[TBL] [Abstract][Full Text] [Related]
12. Anti-anginal and anti-ischemic effects of late sodium current inhibition.
Wimmer NJ; Stone PH
Cardiovasc Drugs Ther; 2013 Feb; 27(1):69-77. PubMed ID: 23247666
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine (Roche Bioscience).
Jones R
IDrugs; 1999 Dec; 2(12):1353-62. PubMed ID: 16113967
[TBL] [Abstract][Full Text] [Related]
14. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
Maier LS
J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
[TBL] [Abstract][Full Text] [Related]
15. Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(5):1-70. PubMed ID: 23074496
[TBL] [Abstract][Full Text] [Related]
16. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
17. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
Chaitman BR; Sano J
Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I25-30. PubMed ID: 18373327
[TBL] [Abstract][Full Text] [Related]
19. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
20. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
